Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool
The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now
Already have access? Login below
